



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 12, 2012

Via E-mail

Xue Bangyi  
Chief Executive Officer  
Jinzanghuang Tibet Pharmaceuticals, Inc.  
Harborside Financial Center  
2500 Plaza V  
Jersey City, NJ 07303

**Re: Jinzanghuang Tibet Pharmaceuticals, Inc.**  
**Form 10-K for the Fiscal Year Ended June 30, 2010**  
**Filed September 28, 2010**  
**Form 10-K for the Fiscal Year Ended June 30, 2011**  
**Filed October 14, 2011**  
**File No. 000-53254**

Dear Mr. Bangyi:

We have completed our review of your filings. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filings and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings to be certain that the filings include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/Tia L. Jenkins

Tia L. Jenkins  
Senior Assistant Chief Accountant  
Office of Beverages, Apparel and  
Mining